Welcome to the fifth edition of Biosimilars Newsletter, a quarterly publication dedicated to keeping you updated on current biosimilars news, including the global regulatory landscape, biosimilars articles and reports, and company news as reported via company press releases. This edition's "hot topic" explores some of the unique operational challenges associated with the development of a biosimilar product and how these issues can be addressed from the outset in strategic planning.
The Value Of Biobetters
The market of biologics is growing at a nearly twice the rate of pharma as a whole. Biologics are expected to account for approximately 17% of total…
Biosimilars Fact Sheet
Biosimilar drug development is unique and complex. At PRA, our cross-functional team of experts guide you through the many nuances of the biosimilar…
Our collaborative, cross-functional team develops tailored, cost-effective services to meet the unique needs of biosimilars clinical development.